|
1
|
Rahib L, Smith BD, Aizenberg R, Rosenzweig
AB, Fleshman JM and Matrisian LM: Projecting cancer incidence and
deaths to 2030: The unexpected burden of thyroid, liver, and
pancreas cancers in the United States. Cancer Res. 74:2913–2921.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Adamska A, Domenichini A and Falasca M:
Pancreatic ductal adenocarcinoma: Current and evolving therapies.
Int J Mol Sci. 18:E13382017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lewis AR, Pihlak R and McNamara MG: The
importance of quality-of-life management in patients with advanced
pancreatic ductal adenocarcinoma. Curr Probl Cancer. 42:26–39.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Uddin A and Chakraborty S: Role of miRNAs
in lung cancer. J Cell Physiol. 20–Apr;2018.(Epub ahead of print).
View Article : Google Scholar
|
|
6
|
Hwang HW and Mendell JT: MicroRNAs in cell
proliferation, cell death, and tumorigenesis. Br J Cancer.
94:776–780. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wang Y, Bao W, Liu Y, Wang S, Xu S, Li X,
Li Y and Wu S: miR-98-5p contributes to cisplatin resistance in
epithelial ovarian cancer by suppressing miR-152 biogenesis via
targeting Dicer1. Cell Death Dis. 9:4472018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Idichi T, Seki N, Kurahara H, Fukuhisa H,
Toda H, Shimonosono M, Okato A, Arai T, Kita Y, Mataki Y, et al:
Molecular pathogenesis of pancreatic ductal adenocarcinoma: Impact
of passenger strand of pre-miR-148a on gene regulation. Cancer Sci.
109:2013–2026. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Liu B, Yang H, Taher L, Denz A, Grützmann
R, Pilarsky C and Weber GF: Identification of prognostic biomarkers
by combined mRNA and miRNA expression microarray analysis in
pancreatic cancer. Transl Oncol. 11:700–714. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Xiong G, Huang H, Feng M, Yang G, Zheng S,
You L, Zheng L, Hu Y, Zhang T and Zhao Y: MiR-10a-5p targets TFAP2C
to promote gemcitabine resistance in pancreatic ductal
adenocarcinoma. J Exp Clin Cancer Res. 37:762018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Liu YA, Zhang Y, Zheng Z, Li K, Wu XH, Du
QG, Ye X, Wang L and Zhu L: MicroRNA-216b reduces growth, migration
and invasion of pancreatic ductal adenocarcinoma cells by directly
targeting ρ-associated coiled-coil containing protein kinase 1.
Oncol Lett. 15:6745–6751. 2018.PubMed/NCBI
|
|
12
|
Sun D, Wang X, Sui G, Chen S, Yu M and
Zhang P: Downregulation of miR-374b-5p promotes chemotherapeutic
resistance in pancreatic cancer by upregulating multiple
anti-apoptotic proteins. Int J Oncol. 14–Mar;2018.(Epub ahead of
print). View Article : Google Scholar
|
|
13
|
Xie F, Huang Q, Liu CH, Lin XS, Liu Z, Liu
LL, Huang DW and Zhou HC: MiR-1271 negatively regulates AKT/MTOR
signaling and promotes apoptosis via targeting PDK1 in pancreatic
cancer. Eur Rev Med Pharmacol Sci. 22:678–686. 2018.PubMed/NCBI
|
|
14
|
Zhu W, Wang Y, Zhang D, Yu X and Leng X:
MiR-7-5p functions as a tumor suppressor by targeting SOX18 in
pancreatic ductal adenocarcinoma. Biochem Biophys Res Commun.
497:963–970. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yuan Q, Zhang Y, Li J, Cao G and Yang W:
High expression of microRNA-4295 contributes to cell proliferation
and invasion of pancreatic ductal adenocarcinoma by the
down-regulation of Glypican-5. Biochem Biophys Res Commun.
497:73–79. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Xia D, Li X, Niu Q, Liu X, Xu W, Ma C, Gu
H, Liu Z, Shi L, Tian X, Chen X and Zhang Y: MicroRNA-185
suppresses pancreatic cell proliferation by targeting
transcriptional coactivator with PDZ-binding motif in pancreatic
cancer. Exp Ther Med. 15:657–666. 2018.PubMed/NCBI
|
|
17
|
Wanet A, Tacheny A, Arnould T and Renard
P: miR-212/132 expression and functions: Within and beyond the
neuronal compartment. Nucleic Acids Res. 40:4742–4753. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Xie M, Fu Z, Cao J, Liu Y, Wu J, Li Q and
Chen Y: MicroRNA-132 and microRNA-212 mediate doxorubicin
resistance by down-regulating the PTEN-AKT/NF-κB signaling pathway
in breast cancer. Biomed Pharmacother. 102:286–294. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wu Z, Zhou L, Ding G and Cao L:
Overexpressions of miR-212 are associated with poor prognosis of
patients with pancreatic ductal adenocarcinoma. Cancer Biomark.
18:35–39. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Jia P, Wei G, Zhou C, Gao Q, Wu Y, Sun X
and Li X: Upregulation of MiR-212 inhibits migration and
tumorigenicity and inactivates Wnt/β-catenin signaling in human
hepatocellular carcinoma. Technol Cancer Res Treat.
17:15330346187652212018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hu B, Jin X and Wang J: MicroRNA-212
targets mitogen-activated protein kinase 1 to inhibit proliferation
and invasion of prostate cancer cells. Oncol Res. 26:1093–1102.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tang T, Huan L, Zhang S, Zhou H, Gu L,
Chen X and Zhang L: MicroRNA-212 functions as a tumor-suppressor in
human non-small cell lung cancer by targeting SOX4. Oncol Rep.
38:2243–2250. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Jiang C, Wang H, Zhou L, Jiang T, Xu Y and
Xia L: MicroRNA-212 inhibits the metastasis of nasopharyngeal
carcinoma by targeting SOX4. Oncol Rep. 38:82–88. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhao T, Jiang W, Wang X, Wang H, Zheng C,
Li Y, Sun Y, Huang C, Han ZB, Yang S, et al: ESE3 inhibits
pancreatic cancer metastasis by upregulating E-cadherin. Cancer
Res. 77:874–885. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Whatcott CJ, Diep CH, Jiang P, Watanabe A,
LoBello J, Sima C, Hostetter G, Shepard HM, Von Hoff DD and Han H:
Desmoplasia in primary tumors and metastatic lesions of pancreatic
cancer. Clin Cancer Res. 21:3561–3568. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Liu H, Ma Q, Xu Q, Lei J, Li X, Wang Z and
Wu E: Therapeutic potential of perineural invasion, hypoxia and
desmoplasia in pancreatic cancer. Curr Pharm Des. 18:2395–2403.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Akakura N, Kobayashi M, Horiuchi I, Suzuki
A, Wang J, Chen J, Niizeki H, Kawamura Ki, Hosokawa M and Asaka M:
Constitutive expression of hypoxia-inducible factor-1alpha renders
pancreatic cancer cells resistant to apoptosis induced by hypoxia
and nutrient deprivation. Cancer Res. 61:6548–6554. 2001.PubMed/NCBI
|
|
29
|
Dengler VL, Galbraith M and Espinosa JM:
Transcriptional regulation by hypoxia inducible factors. Crit Rev
Biochem Mol Biol. 49:1–15. 2014. View Article : Google Scholar : PubMed/NCBI
|
